Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1, Open-label, Two Routes IV and Intra-hepatic Artery Dose-escalation Clinical Study to Evaluate the Safety and Efficacy of ET1402L1-CAR T- Cells in AFP Expressing Hepatocellular Carcinoma (HCC)

Next Previous
Trial Profile

Phase 1, Open-label, Two Routes IV and Intra-hepatic Artery Dose-escalation Clinical Study to Evaluate the Safety and Efficacy of ET1402L1-CAR T- Cells in AFP Expressing Hepatocellular Carcinoma (HCC)

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 05 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ET1402L1 CART (Primary) ; ET1402L1 CART (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors Aeon Therapeutics

Most Recent Events

  • 27 Jun 2019 Status changed from recruiting to discontinued.
  • 05 Sep 2018 Results published in the Eureka Therapeutics Media Release
  • 05 Sep 2018 Acording to Eureka Therapeutics media release, today announced preliminary safety and clinical results from this study. The data was presented today in the late-breaking abstracts session of the CAR-TCR Summit in Boston, Massachusett.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top